Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock
May 16, 2022 07:28 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals Appoints Oncology Clinical Development Veteran Dr. Kimberly Blackwell as Chief Executive Officer
May 16, 2022 07:00 ET
|
ZENTALIS PHARMACEUTICALS
Dave Johnson appointed as Chairman of the Board Anthony Sun, MD, former CEO of Zentalis, to remain CEO of joint venture, Zentera Therapeutics NEW YORK and SAN DIEGO, May 16, 2022 ...
Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update
May 05, 2022 07:00 ET
|
ZENTALIS PHARMACEUTICALS
Announced initial data on ZN-c3 in combination with chemotherapy in advanced ovarian cancer and interim data on ZN-c3 in uterine serous carcinoma (USC) at AACR Received a $25 million equity...
Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer
April 27, 2022 07:00 ET
|
ZENTALIS PHARMACEUTICALS
Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells Adam Schayowitz, Ph.D., MBA, Vice...
Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR
April 11, 2022 16:01 ET
|
ZENTALIS PHARMACEUTICALS
ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all evaluable chemotherapy cohorts ZN-c3 demonstrated...
Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR
April 08, 2022 13:00 ET
|
ZENTALIS PHARMACEUTICALS
ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all evaluable chemotherapy cohorts ZN-c3 in combination...
Zentalis Pharmaceuticals and Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies, Initially Focused on the Wee1 Inhibitor ZN-c3
March 29, 2022 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals Announces First Patient Dosed in the Potentially Registrational Phase 1/2 Study of BCL-2 inhibitor ZN-d5 in Patients with Relapsed or Refractory Light Chain (AL) Amyloidosis
March 22, 2022 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
March 09, 2022 16:01 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2022
March 08, 2022 16:30 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...